The CLIMB Act Could Finally Bring Wall Street to Cannabis
Advertisement
Table of Contents
- A $30 Billion Industry Locked Out of the Financial System
- The Banking Problem Explained
- What the CLIMB Act Would Do
- The Tax Relief Connection
- Political Landscape and Prospects
- Market and Investor Reaction
- What Comes Next
A $30 Billion Industry Locked Out of the Financial System
The U.S. cannabis industry generates an estimated $30.5 billion in annual revenue, employs hundreds of thousands of workers, and operates legally in dozens of states. Yet the vast majority of cannabis businesses remain effectively barred from the basic financial services that every other legitimate industry takes for granted.
That could change with the Capital Lending and Investment for Marijuana Businesses (CLIMB) Act, a bipartisan bill introduced in March 2026 that represents the most comprehensive attempt yet to solve the cannabis industry's financial services crisis. If enacted, the legislation would allow state-licensed cannabis operators to access banking services, obtain business loans, and even list on major U.S. stock exchanges.
The Banking Problem Explained
Cannabis businesses operate in a regulatory twilight zone. While legal under state law in 38 states plus Washington, D.C., marijuana remains a Schedule I [Quick Definition: The most restrictive federal drug classification, currently including heroin and cannabis] controlled substance under federal law, even as the rescheduling process initiated by President Trump's executive order works its way through federal agencies.
This federal-state conflict creates enormous practical problems. Banks and credit unions are federally regulated and risk severe penalties, including loss of their federal charter, for knowingly servicing businesses that traffic in controlled substances. The result is that most cannabis companies operate on a cash-only or cash-heavy basis, creating security risks, accounting challenges, and barriers to growth.
The numbers tell the story. According to the Financial Crimes Enforcement Network, only about 800 banks and credit unions nationally have reported servicing cannabis-related businesses, out of roughly 9,000 total banking institutions. Many of those that do serve the industry charge premium fees, require excessive compliance documentation, and offer limited services.
For cannabis companies, the consequences are severe. Without access to standard commercial banking, businesses cannot easily accept credit card payments, maintain payroll systems, access lines of credit, or obtain the business loans that fund expansion in every other industry. The practical reality for many operators involves armored vehicles, cash counting rooms, and a vulnerability to robbery that would be unthinkable for any other multibillion-dollar sector.
What the CLIMB Act Would Do
The legislation attacks the cannabis banking problem on multiple fronts, going well beyond the scope of previous safe banking proposals that focused narrowly on shielding banks from federal prosecution.
The most headline-grabbing provision would allow state-approved cannabis operators to list their shares on major U.S. stock exchanges like the NYSE and Nasdaq. Currently, publicly traded cannabis companies are relegated to Canadian exchanges or U.S. over-the-counter markets, limiting their access to institutional capital and creating liquidity challenges for investors.
This provision alone could transform the industry's capital structure. Multi-state operators [Quick Definition: Cannabis companies licensed in multiple states] that currently trade on the Canadian Securities Exchange at depressed valuations would gain access to the deep pools of institutional capital that flow through major U.S. exchanges. Index fund inclusion, institutional portfolio allocation, and increased analyst coverage would all follow listing on a major exchange.
The bill also provides explicit safe harbor protections for financial institutions that service cannabis businesses operating in compliance with state law. Banks, credit unions, insurance companies, and other financial services providers would be shielded from federal prosecution, regulatory sanctions, and asset forfeiture for providing standard services to legal cannabis companies.
Beyond banking, the CLIMB Act addresses lending. Cannabis businesses have been largely shut out of the commercial lending market, forcing many to rely on high-interest private capital or dilutive equity financing. The legislation would allow the Small Business Administration to extend loans to cannabis businesses for the first time, while also permitting commercial banks to make standard business loans to the sector.
The Tax Relief Connection
The CLIMB Act arrives alongside another major financial development for the cannabis industry: the potential elimination of Section 280E [Quick Definition: IRS code barring cannabis businesses from deducting normal expenses like rent and payroll] of the Internal Revenue Code as a burden on cannabis companies.
Under current law, Section 280E prevents businesses that traffic in Schedule I or II controlled substances from deducting ordinary business expenses. For cannabis companies, this effectively means paying taxes on gross revenue rather than net income, resulting in effective tax rates that can exceed 70 percent.
If marijuana is successfully rescheduled to Schedule III [Quick Definition: A mid-level federal drug classification including ketamine and testosterone], as directed by President Trump's executive order, 280E would no longer apply to cannabis businesses. Industry analysts estimate this would provide a collective $2.3 billion tax break to the sector, transforming the financial viability of companies that have operated under crushing tax burdens.
Combined with the CLIMB Act's banking and exchange listing provisions, the one-two punch of tax relief and financial access could fundamentally restructure the cannabis industry's economics. Companies that have survived on razor-thin margins while paying punitive tax rates would suddenly have access to normal business finance, potentially triggering a wave of investment, expansion, and consolidation.
Political Landscape and Prospects
The CLIMB Act's bipartisan sponsorship reflects growing consensus in Congress that the cannabis banking problem requires legislative action. Both Republican and Democratic members have championed various versions of cannabis banking reform over the past several years, with the SAFE Banking Act [Quick Definition: Federal bill that would let banks serve cannabis businesses without fear of prosecution] repeatedly passing the House before stalling in the Senate.
What makes the CLIMB Act different from previous attempts is its comprehensive scope. Rather than addressing banking alone, it tackles the full spectrum of financial services challenges facing the industry. Proponents argue this broader approach makes the legislation more durable and meaningful, even if it also makes passage more politically complex.
The bill faces headwinds from members who oppose any normalization of the cannabis industry and from banking industry lobbyists who want narrower, more targeted legislation with clearer regulatory guidance. Some financial institutions have expressed concern that even with safe harbor protections, the compliance burden of servicing cannabis businesses would remain prohibitively expensive without detailed regulatory frameworks.
Congressional observers give the CLIMB Act reasonable odds of advancing through committee, but caution that floor votes in both chambers are far from guaranteed. The upcoming midterm elections add political complexity, as some members may be reluctant to take a public position on cannabis legislation in competitive districts.
Market and Investor Reaction
Wall Street has responded to the CLIMB Act with cautious optimism. Cannabis-focused exchange-traded funds saw modest gains following the bill's introduction, though investors remain skeptical about the timeline for passage and implementation.
Institutional investors, who have largely avoided cannabis due to its federal legal status, have signaled that exchange listing on major U.S. markets would be a prerequisite for meaningful portfolio allocation. Several large asset management firms have indicated they would begin coverage of cannabis stocks if they were listed on the NYSE or Nasdaq, potentially bringing billions of dollars of institutional capital into the sector.
For existing cannabis companies, the prospect of U.S. exchange listing has already begun to influence strategic decisions. Multi-state operators are positioning themselves for potential uplisting by improving financial reporting, strengthening governance structures, and building the kind of corporate infrastructure that institutional investors expect.
The venture capital and private equity landscape for cannabis could also shift dramatically. Currently, many mainstream investment funds are prohibited by their own charters from investing in federally illegal industries. The CLIMB Act would remove this barrier, potentially unlocking a new wave of growth capital for cannabis startups and expansion-stage companies.
What Comes Next
The CLIMB Act faces a long legislative road, but its introduction marks an important escalation in the cannabis industry's push for financial normalization. Even if the bill doesn't pass in its current form, its provisions are likely to influence future legislative efforts and regulatory actions.
In the near term, the cannabis industry continues to operate under the constraints of limited banking access and punitive taxation. But for the first time, there is a plausible legislative pathway to resolving both of these challenges simultaneously. For an industry that has built a $30 billion market despite operating at an enormous financial disadvantage, the prospect of finally playing on a level field is nothing short of transformative.
The question is no longer whether cannabis will be integrated into the mainstream financial system, but when and how. The CLIMB Act offers one answer, and the industry is watching closely to see if Congress will finally deliver.
Pull-Quote Suggestions:
"Industry analysts estimate this would provide a collective $2.3 billion tax break to the sector, transforming the financial viability of companies that have operated under crushing tax burdens."
"For an industry that has built a $30 billion market despite operating at an enormous financial disadvantage, the prospect of finally playing on a level field is nothing short of transformative."
"The U.S. cannabis industry generates an estimated $30.5 billion in annual revenue, employs hundreds of thousands of workers, and operates legally in dozens of states."
Why It Matters: The bipartisan CLIMB Act aims to give cannabis companies access to banking, loans, and US stock exchanges. Here's what it means for the $30 billion industry.